Clear All
11465 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
55135-0132-01 55135-0132 SACITUZUMAB GOVITECAN TRODELVY 180.0 mg/1 Immunotherapy Drug Antibody Conjugate Trop-2 Intravenous Apr 23, 2020 In Use
50242-0092-86 50242-0092 ENTRECTINIB Rozlytrek 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRKA, TRKB, TRKC, ROS1, ALK Oral Aug 15, 2019 No Longer Used
50242-0094-90 50242-0094 ENTRECTINIB Rozlytrek 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRKA, TRKB, TRKC, ROS1, ALK Oral Aug 15, 2019 In Use
50242-0094-47 50242-0094 ENTRECTINIB Rozlytrek 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRKA, TRKB, TRKC, ROS1, ALK Oral Aug 15, 2019 In Use
50242-0091-30 50242-0091 ENTRECTINIB Rozlytrek 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRKA, TRKB, TRKC, ROS1, ALK Oral Aug 15, 2019 In Use
50242-0623-42 50242-0623 ENTRECTINIB Rozlytrek 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRKA, TRKB, TRKC, ROS1, ALK Oral Oct 20, 2023 In Use
50242-0092-01 50242-0092 ENTRECTINIB Rozlytrek 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRKA, TRKB, TRKC, ROS1, ALK Oral Aug 15, 2019 No Longer Used
50242-0091-86 50242-0091 ENTRECTINIB Rozlytrek 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRKA, TRKB, TRKC, ROS1, ALK Oral Aug 15, 2019 In Use
50419-0392-01 50419-0392 LAROTRECTINIB VITRAKVI 20.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor TRK OROPHARYNGEAL Jul 26, 2019 In Use
50419-0391-01 50419-0391 LAROTRECTINIB VITRAKVI 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRK Oral Jul 26, 2019 In Use
50419-0390-01 50419-0390 LAROTRECTINIB VITRAKVI 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRK Oral Jul 26, 2019 In Use
50419-0393-03 50419-0393 LAROTRECTINIB VITRAKVI 20.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor TRK OROPHARYNGEAL Dec 6, 2022 In Use
71777-0391-01 71777-0391 LAROTRECTINIB VITRAKVI 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRK Oral Nov 26, 2018 In Use
71777-0390-01 71777-0390 LAROTRECTINIB VITRAKVI 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRK Oral Nov 26, 2018 In Use
71777-0392-01 71777-0392 LAROTRECTINIB VITRAKVI 20.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor TRK Oral Nov 26, 2018 In Use
62856-0001-10 62856-0001 Altretamine Hexalen 50.0 mg/1 Chemotherapy Alkylating Agent Triazines Oral Dec 26, 1990 Dec 31, 2019 No Longer Used
65597-0801-01 65597-0801 Datopotamab Deruxtecan DATROWAY 100.0 mg/5mL Immunotherapy Drug Antibody Conjugate Topoisomerase I, TROP2 Intravenous Jan 17, 2025 In Use
65597-0406-01 65597-0406 fam-trastuzumab deruxtecan-nxki Enhertu 100.0 mg/5mL Immunotherapy Drug Antibody Conjugate Topoisomerase I Inhibitor Intravenous Dec 20, 2019 In Use
51144-0003-01 51144-0003 Tisotumab vedotin TIVDAK 40.0 mg/4mL Immunotherapy Drug Antibody Conjugate Tissue factor Intravenous Sep 20, 2021 In Use
00480-1242-28 00480-1242 Lenalidomide Lenalidomide 5.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 3, 2022 In Use
59572-0420-21 59572-0420 Lenalidomide Revlimid 20.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Jun 10, 2013 In Use
59572-0501-00 59572-0501 Pomalidomide Pomalyst 1.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 18, 2013 In Use
47781-0488-01 47781-0488 Lenalidomide LENALIDOMIDE 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 3, 2022 In Use
59572-0415-21 59572-0415 Lenalidomide Revlimid 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Jul 7, 2006 In Use
31722-0258-01 31722-0258 LENALIDOMIDE LENALIDOMIDE 5.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral May 11, 2023 In Use

Found 11465 results — Export these results